Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Human biomonitoring in health risk assessment in Europe: Current practices and recommendations for the future

  • Louro, Henriqueta
  • Heinälä, Milla
  • Bessems, Jos
  • Buekers, Jurgen
  • Vermeire, Theo
  • Woutersen, Marjolijn
  • van Engelen, Jacqueline
  • Borges, Teresa
  • Rousselle, Christophe
  • Ougier, Eva
  • Alvito, Paula
  • Martins, Carla
  • Assunção, Ricardo
  • Silva, Maria João
  • Pronk, Anjoeka
  • Schaddelee-Scholten, Bernice
  • De Alba-González, Mercedes
  • Castaño, Argelia
  • Gonzalez, Carlos
  • Viegas, Susana
  • Humar-Juric, Tatjana
  • Kononenko, Lijana
  • Lampen, Alfonso
  • Vinggaard, Anne Marie
  • Schoeters, Greet
  • Kolossa-Gehring, Marike
  • Santonen, Tiina
Human biomonitoring (HBM) is an important tool to survey the internal exposure of humans which represents the real life chemical body burden to chemicals and/or their metabolites. It results from total exposure to chemical substances from different sources and via different routes. These substances may be regulated under different legislative frameworks on chemicals (e.g., environmental, occupational, food safety etc). In occupational health, HBM has long traditions to control the exposures at workplaces. By providing accurate data on internal exposure, HBM data can improve human health risk assessment (RA) for both the general population and workers. Although the past few years have shown good examples on the use of HBM in the RA of chemicals, there is still quite some work to be done to improve its use in a regulatory RA. Under the scope of the European Human Biomonitoring Initiative (project HBM4EU, 2017-2021), the current study reviews the state-of-the-art of HBM use in chemicals RA with a special focus in Europe, and attempts to identify hurdles and challenges faced by regulators. To gather information on the use of HBM, including the availability of guidance on how to use it in RA, the RA schemes applied by different European or international organizations were analysed. Examples of such use were identified for a few selected groups of chemicals of concern for human health. In addition, we present the results of a survey, aimed at collecting information from national regulatory risk assessors on their day-to-day RA practices, the use of HBM data, and the obstacles and challenges related to their use. The results evidenced and explained some of the current obstacles of using HBM data in RA. These included the lack of HBM guidance values or biomonitoring equivalents (BEs), limited toxicokinetic information to support the interpretation of HBM data and, in the occupational health and safety (OSH) field, the lack of legal enforcement. Therefore, to support the integration of HBM in regulatory RA, we recommend, on one hand, the elaboration of a EU level guidance on the use of HBM in RA and, on the other hand, the continuation of research efforts to integrate HBM with new RA approaches using in vitro/in silico data and Adverse Outcome Pathways (AOPs).
Repisalud
Publication Artículo científico (JournalArticle)

Towards Harmonized Biobanking for Biomonitoring: A Comparison of Human Biomonitoring-Related and Clinical Biorepositories

  • Lermen, Dominik
  • Gwinner, Frederik
  • Bartel-Steinbach, Martina
  • Mueller, Sabine C
  • Habermann, Jens K
  • Balwir, Matharoo-Ball
  • Smits, Elke
  • Virgolino, Ana
  • Fiddicke, Ulrike
  • Berglund, Marika
  • Åkesson, Agneta
  • Bergstrom, Anna
  • Leander, Karin
  • Horvat, Milena
  • Snoj Tratnik, Janja
  • Posada De la Paz, Manuel
  • Castaño, Argelia
  • Esteban-Lopez, Marta
  • von Briesen, Hagen
  • Zimmermann, Heiko
  • Kolossa-Gehring, Marike
Human biomonitoring (HBM) depends on high-quality human samples to identify status and trends in exposure and ensure comparability of results. In this context, much effort has been put into the development of standardized processes and quality assurance for sampling and chemical analysis, while effects of sample storage and shipment on sample quality have been less thoroughly addressed. To characterize the currently applied storage and shipment procedures within the consortium of the European Human Biomonitoring Initiative (HBM4EU), which aims at harmonization of HBM in Europe, a requirement analysis based on data from an online survey was conducted. In addition, the online survey was addressed to professionals in clinical biobanking represented by members of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) to identify the current state-of-the-art in terms of sample storage and shipment. Results of this survey conducted in these two networks were compared to detect processes with potential for optimization and harmonization. In general, many similarities exist in sample storage and shipment procedures applied by ESBB members and HBM4EU partners and many requirements for ensuring sample quality are already met also by HBM4EU partners. Nevertheless, a need for improvement was identified for individual steps in sample storage, shipment, and related data management with potential impact on sample and data quality for HBM purposes. Based on these findings, recommendations for crucial first steps to further strengthen sample quality, and thus foster advancement in HBM on a pan-European level are given.
Repisalud
Publication Artículo científico (JournalArticle)

Learning from previous work and finding synergies in the domains of public and environmental health: EU-funded projects BRIDGE Health and HBM4EU

  • David, Madlen
  • Schwedler, Gerda
  • Reiber, Lena
  • Tolonen, Hanna
  • Andersson, Anna-Maria
  • Esteban-Lopez, Marta
  • Joas, Anke
  • Schöpel, Miriam
  • Polcher, Alexandra
  • Kolossa-Gehring, Marike
Background: During the last decade, the European Union initiated several projects in the domains of public and environmental health. Within this framework, BRIDGE Health (Bridging Information and Data Generation for Evidence-based Health policy and Research) and HBM4EU (European human biomonitoring initiative) have been implemented. Whereas, the focus of BRIDGE Health was towards a sustainable and integrated health information system (HIS), the aim of HBM4EU is to improve evidence of the internal exposure of European citizens to environmental chemicals by human biomonitoring (HBM) and the impact of internal exposure on health. As both, environmental and public health determinants are important for health promotion, disease prevention and policy, BRIDGE Health and HBM4EU have overlapping aims and outcomes. In order to improve health information regarding public health and environmental health issues, best use and exchange of respective networks and project results is necessary. Methods: Both projects have implemented health information (HI) and HBM tasks in order to provide adequate environmental and public health information of the European population. Synergies of the projects were identified in the working progress and because of overlapping networks and experts a focused analysis of both projects was envisaged. This paper elaborates on the aims and outcomes of both projects and the benefit of merging and channelling research results for the use of better health information and policy making that may be of relevance for any other project in these research fields. Results: The need for focused exchanges and collaborations between the projects were identified and benefits of exchanges were highlighted for the specific areas of indicator development, linkage of data repositories and the combination of HBM studies and health examination surveys (HES). Further recommendations for a European wide harmonisation among different tasks in the fields of public health and environmental health are being developed. Conclusions: Lessons learned from HBM4EU and BRIDGE Health show that continuous efforts must be undertaken, also by succeeding projects, to guarantee the exchange between public health and environmental health issues. Networks covering both are essential to provide better evidence of knowledge. The experiences from BRIDGE Health and HBM4EU give a valuable input for any future activity in these domains. Avoiding overlaps and streamlining further exchange of public health and environmental health contributes to best use of research results and allows to develop new strategies and tools for improvement of health information and thus enhances people's health and well-being.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

Towards harmonised criteria in quality assurance and quality control of suspect and non-target LC-HRMS analytical workflows for screening of emerging contaminants in human biomonitoring

  • Caballero-Casero, Noelia
  • Belova, Lidia
  • Vervliet, Philippe
  • Antignac, Jean-Philippe
  • Castaño, Argelia
  • Debrauwer, Laurent
  • Esteban López, Marta
  • Huber, Carolin
  • Klanova, Jana
  • Krauss, Martin
  • Lommen, Arjen
  • Mol, Hans G.J.
  • Oberacher, Herbert
  • Pardo, Olga
  • Price, Elliott J.
  • Reinstadler, Vera
  • Vitale, Chiara Maria
  • Van Nuijs, Alexander L.N.
  • Covaci, A.
Although the exposure assessment of chemicals of emerging concern (CECs) has taken a decisive step forward through advances in (bio)informatics, statistics, and the development of highly sophisticated analytical instruments, the lack of standardisation and harmonisation of analytical workflows and method performance assessment for suspect and non-target screening hampers the interpretation of results, their comparability and thus, its transmission to policymakers. To date, unlike in other research fields such as forensics or food analysis, there is a lack of guidelines for non-target analysis in human risk assessment and quality assurance and quality control (QA/QC) protocols. Moreover, the majority of efforts have been focused on the development and implementation of QA/QC actions for data acquisition, data analysis and mining, largely neglecting the sample preparation necessary for determination of CECs by suspect and non-target screening methods. In this article, we propose a set of QA/QC measures that covers sampling, sample preparation and data acquisition, as an aspect of work conducted within the European Biomonitoring for Europe initiative (HBM4EU). These measures include the use of standardised terminology and the implementation of dedicated QA/QC actions in each stage of the analytical process. Moreover, a framework for the analytical performance assessment has been developed for the first time for the identification of CECs in human samples by suspect and non-target approaches. Adoption of the actions proposed here for the identification of CECs in human matrices can significantly improve the comparability of reported results and contribute to the (challenging) Exposome research field.